用於體重控制，做為低熱量飲食及增加體能活動外之輔助療法

Anorexiant; Antidepressant, Dopamine/Norepinephrine-Reuptake Inhibitor; Opioid Antagonist

Naltrexone:
Absorption: almost complete.
Distribution: ~1350 L.
Protein binding: 21%.
Bioavailability: Variable range (5% to 40%).
Half-life elimination: 4 hours.
Time to peak, serum: ~60 minutes.
Excretion: Primarily urine.
Bupropion:
Duration of action: 1 to 2 days.
Absorption: Rapid.
Distribution: ~20 to 47 L/kg.
Protein binding: 84%.
Distribution: 3 to 4 hours.
Time to peak, serum: within 3 hours.
Metabolite: ~6 to 7 hours.
Excretion: Urine (87%); feces (10%).

Hypersensitivity to bupropion, naltrexone, or any other component of the formulation; concomitant use of other bupropion-containing products, chronic opioid, opiate agonist, or partial agonist use; patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiseizure drugs; concomitant use of MAOIs; initiation of naltrexone/bupropion in a patient receiving linezolid or IV methylene blue.

Information related to the use of this combination in pregnancy is limited.

Naltrexone, bupropion, and their metabolites are present in breast milk.

>10%: headache (18%), sleep disorder (14%), nausea (33%), constipation (19%), vomiting (11%).
1% to 10%: hypertension (≤6%), increased blood pressure (≤6%), palpitations (2%), myocardial infarction (<2%), tachycardia (<2%), dizziness (10%), insomnia (9%), depression (6%), anxiety (4% to 6%), fatigue (4%), irritability (3%), abnormal dreams (<2%), altered mental status (<2%), equilibrium disturbance (<2%), feeling abnormal (<2%), intention tremor (<2%), , lethargy (<2%), memory impairment (<2%), nervousness (<2%), tension (<2%), vertigo (<2%), hyperhidrosis (3%), alopecia (<2%), hot flash (4%), dehydration (<2%), increased thirst (<2%), xerostomia (8%), diarrhea (7%), upper abdominal pain (4%), viral gastroenteritis (4%), abdominal pain (3%), tinnitus (3%), increased serum creatinine (<2%), pneumonia (<2%).

Weight management, chronic (alternative agent):
Initial: 1 tablet once daily in the morning for 1 week; increase as tolerated in weekly intervals: 1 tablet twice daily for 1 week; then 2 tablets in the morning and 1 tablet in the evening for 1 week; and then 2 tablets twice daily (maximum dose: 4 tablets/day); Consider discontinuation if weight loss is <4% to 5% of baseline after 3 months.

Mild impairment: No dosage adjustment necessary.
Moderate or severe impairment: Maximum dose: One tablet twice daily.
End-stage renal disease: Use is not recommended.

Mild impairment: No dosage adjustment necessary.
Moderate impairment: Maximum dose: One tablet twice daily.
Severe impairment: Use is not recommended.